All big players in the pharma industry are concerned with AI adoption, the tech has become a strategic priority, among other things and all leading players of the pharmaceutical industry will be moving towards "platform-based drug design" with specific focus on the emergence of comprehensive R&D and business infrastructure that enables end-to-end AI-driven drug development.

About 90% of large pharmaceutical firms-initiated AI projects in 2021, an increase in AI-based partnerships up 575% in six years. In addition, the Artificial intelligence in the drug discovery market is expected to gain market growth to USD $3932 million by 2029.

Pharma IQ Live: Utilizing AI in Drug Discovery will be focused on:
 

• Technically integrating and apply AI algorithms to enhance trial design, improve patient selection and retention and achieve more precise pharmacovigilance studies.
• Grasping how AI can fundamentally change the paradigm of clinical trial execution and identify key areas where AI can positively impact your drug development decision making.
• Harnessing AI to extract maximum value to achieve regulatory success and accelerate novel therapeutic products to market
• Assessing the strategic role AI is playing in the emerging “data-centric” model of innovation
• Providing an increased understanding of AI mechanics with a focus on AI-driven tools and approaches
• Improving decision-making through analysis of data sets to generate novel insights and identify novel drug candidates
• Eliminating blind spots in research and generate insights from thousands of unrelated data sources